The first experience of tracheal recanalization by tumor resection with Nd-YAG-laser

Actuality. Tracheal cancer is a rare disease which amounts up to 0.2% of the total number of cancers. Currently, there is an increase in the number of patients with impaired tracheal patency. Endoscopic procedures are most commonly used to restore and maintain the tracheal lumen. The key treatment for primary cancer is a surgical one; however, due to late diagnostics, the tumor is often inoperable. Chemotherapy for tracheal cancer is ineffective, and practically is not used. At present, endoscopic tracheal recanalization with laser vaporization is a method of choice in patients with inoperable tracheal tumors.Objective: to improve outcomes in patients with inoperable primary tracheal cancer using Nd-YAG laser either as the fi rst component of staged treatment strategy, or as the fi nal volume treatment.Methods. Patient K., 75 years old, was admitted to the hospital with complaints of dyspnea at rest, weakness and hemoptysis. As anamnesis showed, the patient had noticed a deterioration in her breathing during the last 6 months. CT scan revealed a volumetric formation (tumor) of the cervicothoracic trachea (8.0 cm above the bifurcation) with 90% stenosing in the lumen. When performing tracheobronchoscopy in the cervicothoracic trachea, a broad-based lumpy tumor, 5 cm long, stenosing the tracheal lumen by 2/3 was found on the posterior wall. Morphological examination of biopsy material revealed adenocystic carcinoma.Results. The performed endoscopic examination with neodymium YAG laser recanalization demonstrated the advantage of this technique in patients with inoperable tracheal tumors.Conclusion. Endoscopic recanalization of the trachea with neodymium YAG laser has been proven to be effective in patients with inoperable tracheal cancer. It improves their quality of life as well.

Download Full-text

Compare Brimonidine 0.2% versus Latanoprost 0.005% (Xalatan) in preventing intraocular pressure after YAG laser posterior capsulotomy in patients visiting ophthalmology clinic in Ardabil city

International Journal of Basic & Clinical Pharmacology ◽

10.18203/2319-2003.ijbcp20164778 ◽

2016 ◽

Vol 6 (1) ◽

pp. 189

Author(s):

Habib Ojaghi ◽

Rahim Masoumi ◽

Solmaz Eskandar-Sani

Keyword(s):

Intraocular Pressure ◽

Double Blind ◽

Yag Laser ◽

Posterior Capsulotomy ◽

Double Blind Clinical Trial ◽

Number Of Patients ◽

Significant Difference ◽

The Mean ◽

Iop Elevation ◽

Neodymium Yag Laser

Background: The transient increase of intraocular pressure (IOP) following neodymium YAG laser capsulotomy can occur in a significant number of patients, which requires prophylactic treatment with IOP reducing drugs, and in some patients, postoperative IOP monitoring. This study was performed to compare the efficacy of brimonidine 0.2% versus latanoprost0.005% (Xalatan) in preventing the IOP elevation after YAG laser posterior capsulotomy in patients visiting ophthalmology clinic in Alavi Hospital.Methods: This study was a randomized, double-blind clinical trial that included 100 patients who had developed posterior capsule opacification (PCO) as a result of previous cataract surgery and were candidate for undergoing YAG laser posterior capsulotomy. The patients were randomly divided into two groups of 50 patients. One group received brimonidine 0.2% one hour before surgery, and the other group received Xalatan 0.005% in the night before laser surgery. In both groups the patients' IOP was measured in baseline, 1, 2, 3, 24 hours, 3 days and one week after surgery. The gathered data were analyzed using statistical methods in SPSS.16.Results: The mean IOP, 1, 2, 3, and 24 hours, 3 days, and one week after surgery didn't show any significant difference between two groups. IOP one hour before surgery changed significantly compared to one hour after surgery and a statistically significant relationship was found between the two groups, though at other times of measurement, the differences were not significant.Conclusions: Results showed that using Brimonidine 0.2% or Latanoprost 0.005% as prophylactic before YAG laser posterior capsulotomy could be effective in preventing IOP after treatment.

Download Full-text